Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Neurology and Neuroscience Reports
Published in: Current Neurology and Neuroscience Reports 2/2012

01-04-2012 | Headache (I Garza, Section Editor)

OnabotulinumtoxinA in Pediatric Chronic Daily Headache

Authors: Marielle Kabbouche, Hope O’Brien, Andrew D. Hershey

Published in: Current Neurology and Neuroscience Reports | Issue 2/2012

Login to get access

Abstract

Chronic migraine occurs in about 3% of pediatric headaches. Many would be intractable to more than two preventive medications. OnabotulinumtoxinA has been approved by the US Food and Drug Administration for the use of chronic migraine in adults in 2010. Data on effectiveness and tolerability in the pediatric population are very limited. The study described in this article is a retrospective review of available data of all patients who received OnabotulinumtoxinA for chronic migraine in a large pediatric headache center from 2004 to 2010. Botox is recommended to any pediatric patient coming to the multidisciplinary clinic for chronic headache if they fail two or more preventive medications. This study showed a major change in the frequency of the headache with a statistical difference in the improvement of headache days per month. There was a 30-point drop in the pediatric disability scoring between first injection and follow-up injection with a change from severe disability to moderate disability.
Literature
1.
Abu-Arefeh I, Russel G. Prevalence of headache and migraine in school children. BMJ (Clinical Research). 1994;309:765–9.CrossRef
2.
•• Dodick W, Turkel C, DeGryse R, Aurora S, Silberstein S, Lipton R, Diener H. OnabotulinumtoxinA for Treatment of Chronic Migraine: Headache: The Journal of Head and Face Pain Volume 50, Issue 6, pages 921–936, June 2010 This is a review of the PREEMPT studies: double-blind placebo-controlled studies on the efficacy of BoNT-A in adults. The FDA approval for chronic migraine in adults was based on these studies. CrossRef
3.
Bigal ME, Lipton RB, Tepper SJ, Rapoport AM, Sheftell FD. Primary chronic daily headache and its subtypes in adolescents and adults. Neurology. 2004;63:843–7.PubMed
4.
Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004;24 Suppl 1:9–160.
5.
•• Ahmed K, Hall Oa K, Mack K, Garza I. Experience with Botulinum Toxin Type A in Medically Intractable Pediatric Chronic Daily Headache. Pediatric Neurology.2010:43 (5), 316-319. This is a rare article describing expert opinion and experience on the use of BoNT-A in the pediatric population; the review is limited to 10 patients and is not a placebo-controlled study but is the only full published manuscript in pediatric use of BoNT-A. All previous submissions have been abstracts to different scientific meetings. PubMedCrossRef
6.
• Hershey AD, Powers S, Vockell AL, LeCates S, Kabbouche MA, Maynard MK. PedMIDAS: development of a questionnaire to assess disability of migraines in children. Neurology. 2001;57:2034–2039 This article describes the factors behind the disability scoring and assessment and is a major tool that is frequently used in clinical practice as well as in research in the pediatric population. PubMed
7.
Castillo J, Muñoz P, Guitera V, Pascual J. Epidemiology of chronic daily headache in the general population. Headache. 1999;39:190–6.PubMedCrossRef
8.
Stang P, Osterhaus J. Impact of migraine in the United States: data from the National Health Interview Survey. Headache. 1993;33:29–35.PubMedCrossRef
9.
Olesen J, Bousser MG, Diener HC, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia. 2006;26:742–6.PubMedCrossRef
Metadata
Title
OnabotulinumtoxinA in Pediatric Chronic Daily Headache
Authors
Marielle Kabbouche
Hope O’Brien
Andrew D. Hershey
Publication date
01-04-2012
Publisher
Current Science Inc.
Published in
Current Neurology and Neuroscience Reports / Issue 2/2012
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-012-0251-1

Other articles of this Issue 2/2012

Current Neurology and Neuroscience Reports 2/2012 Go to the issue

Headache (I Garza, Section Editor)

Recent Advances in Diagnostic Strategies for Giant Cell Arteritis

Sleep (M Thorpy and M Billiard, Section Editors)

Effects of Circadian Disruption on Mental and Physical Health

Clinical Trial Report

Temozolomide for Pediatric High-Grade Gliomas

Sleep (M Thorpy and M Billiard, Section Editors)

REM Sleep Behavior Disorder and REM Sleep Without Atonia as an Early Manifestation of Degenerative Neurological Disease

Pediatric Neurology (R Packer, Section Editor)

Congenital Myopathies: An Update

Erratum

Erratum to: REM Sleep Behavior Disorder and REM Sleep Without Atonia as an Early Manifestation of Degenerative Neurological Disease